To already have $23m revenue locked in for FY16 and $13m for FY17 is an excellent result.
All indications are that their market will continue to grow rapidly.
This was released the other day, "largest increase in Alzheimer's funding to date - US$350m":
http://www.alz.org/news_and_events_senate_makes_history.asp
Ann: Cogstate signs sales contract for Alzheimer's Disease trial, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.84 |
Change
0.050(2.79%) |
Mkt cap ! $312.3M | |||
| Open | High | Low | Value | Volume |
| $1.81 | $1.84 | $1.79 | $19.96K | 11.05K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2500 | $1.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.84 | 1424 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| CGS (ASX) Chart |